AbTis has developed 3rd generation of ADC linker technology, AbClick®.

AbClick® utilizes a cyclic peptide that site-selectively conjugates drugs to natural antibodies without antibody modification. It also controls number of payloads conjugated to the linker for high yield of conjugation and simple process of purification. Therefore, AbClick® leads cost-effective ADC production with a high therapeutic index.